menu
    • menu
    [{"orgOrder":0,"company":"Miravo Healthcare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Naproxen Sodium","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"Miravo Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Miravo Healthcare \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Miravo Healthcare \/ Orion Corporation"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naproxen Sodium","moa":"PG G\/H synthase 1","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"China Pharma Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naproxen Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"China Pharma Holdings","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"China Pharma Holdings \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"China Pharma Holdings \/ Not Applicable"},{"orgOrder":0,"company":"Nuvo Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Naproxen Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Nuvo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvo Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Nuvo Pharmaceuticals \/ Orion Corporation"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naproxen Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Naproxen Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for (-)-Naproxen sodium

    Menu

    (-)-Naproxen sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Strides Pharma Science

                            India
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Strides receives USFDA approval for Naproxen Sodium OTC Softgel Capsules

                            Details : USFDA approved generic version of naproxen sodium, a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps.

                            Brand Name : Naproxen Sodium-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 18, 2022

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Strides Pharma Science

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dr. Reddy's Laboratories

                            India
                            CPhI WW Frankfurt
                            Booth #9.1B48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Dr. Reddy’s Announces the Re-Launch of Over-The-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equ...

                            Details : Dr. Reddy’s OTC Naproxen Sodium Tablets USP, 220 mg is an over-the-counter nonsteroidal antiinflammatory drug (NSAID) for use as a pain reliever and fever reducer. It temporarily relieves minor aches and pains.

                            Brand Name : Naproxen Sodium-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 03, 2021

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Granules India Limited

                            India
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

                            Lead Product(s) : Naproxen Sodium,Diphenhydramine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Granules India Receives FDA Approval for Naproxen Sodium/Diphenhydramine Tablets

                            Details : Generic of Naproxen Sodium and Diphenhydramine HCl Tablets are approved for relief of occasional sleeplessness associated with minor aches and pains and to help you fall asleep and stay asleep.

                            Brand Name : Aleve-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 25, 2020

                            Lead Product(s) : Naproxen Sodium,Diphenhydramine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Granules India

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nuvo Pharmaceuticals

                            Canada arrow
                            PharmaVenue
                            Not Confirmed

                            Nuvo Pharmaceuticals

                            Canada arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naproxen Sodium,Sumatriptan

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Orion Corporation

                            Deal Size : $0.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Searchlight Pharma Announces Suvexx® Launch in Europe, Along with Deal Expansion to all E.U. Markets

                            Details : The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U....

                            Brand Name : Suvexx

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 15, 2023

                            Lead Product(s) : Naproxen Sodium,Sumatriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Orion Corporation

                            Deal Size : $0.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            China Pharma Holdings

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            China Pharma Holdings

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naproxen Sodium,Pseudoephedrine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            China Pharma Holdings, Inc. Announced That Several Products Are Included in The Catalogue of Medicines for Peo...

                            Details : Naproxen Sodium and Pseudoephedrine Hydrochloride Sustained Release Tablets (brand name, Pusen OK), in which the compound ingredient pseudoephedrine is in line with the cold symptom relief medicine recommended in the Catalog.

                            Brand Name : Pusen OK

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 15, 2022

                            Lead Product(s) : Naproxen Sodium,Pseudoephedrine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Miravo Healthcare

                            Canada arrow
                            PharmaVenue
                            Not Confirmed

                            Miravo Healthcare

                            Canada arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naproxen Sodium,Sumatriptan

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Orion Corporation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Miravo Healthcare Ireland Enters into Suvexx® License and Supply Agreement with Orion Corporation for Select ...

                            Details : Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estoni...

                            Brand Name : Suvexx

                            Molecule Type : Small molecule

                            Upfront Cash : $2.0 million

                            December 21, 2020

                            Lead Product(s) : Naproxen Sodium,Sumatriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Orion Corporation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth